Therapie des Typ-1-Diabetes

B. O. Böhm; M. Dreyer; A. Fritsche; M. Füchtenbusch; S. Gölz; S. Martin

doi:10.1055/s-0031-1283876

Diabetologie und Stoffwechsel, Inhaltsverzeichnis

Diabetologie und Stoffwechsel 2012; 7(01): 33-83
DOI: 10.1055/s-0031-1283876

Leitlinie

Therapie des Typ-1-Diabetes

Therapy of Type 1 Diabetes

B. O. Böhm

¹Klinik für Innere Medizin I, Zentrum für Innere Medizin, Universitätsklinikum Ulm

,

M. Dreyer

²Asklepios Westklinikum Hamburg GmbH, Hamburg

,

A. Fritsche

³Klinik für Innere Medizin IV, Universitätsklinikum Tübingen

,

M. Füchtenbusch

⁴Städt. Klinikum München GmbH, Klinikum Schwabing, Tagesklinik für Diabetologie, München

,

S. Gölz

⁵Diabetes Esslingen

,

S. Martin

⁶Leibnitz-Zentrum für Diabetes-Forschung an der Heinrich-Heine-Universität Düsseldorf

Literatur
1 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationales Programm für Versorgungs-Leitlinien. Methoden-Report. 2010 4.. Auflage http://www.versorgungsleitlinien.de/methodik/reports
2 Johnson DD, Palumbo PJ, Chu CP. Diabetic ketoacidosis in a community-based population. Mayo Clin Proc 1980; 55: 83-88
3 Martin S, Kolb H. Pathogenese und Immuntherapie des Diabetes mellitus Typ 1. Diabet Stoffw 1998; 7: 17-24
4 Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2: 1279-1283
5 Palmer JP, Asplin CM, Clemons P et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222: 1337-1339
6 Wiest-Ladenburger U, Hartmann R, Hartmann U et al. Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes 1997; 46: 565-571
7 Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003; 52: 1128-1136
8 Törn C, Mueller PW, Schlosser M et al. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008; 51: 846-852
9 Schlosser M, Mueller PW, Torn C et al. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 2010; 53: 2611-2620
10 Seissler J, Scherbaum WA. Autoimmune diagnostics in diabetes mellitus. Clin Chem Lab Med 2006; 44: 133-137
11 Isermann B, Ritzel R, Zorn M et al. Autoantibodies in diabetes mellitus: current utility and perspectives. Exp Clin Endocrinol Diabetes 2007; 115: 483-490
12 Warncke K, Frohlich-Reiterer EE, Thon A et al. Polyendocrinopathy in children, adolescents, and young adults with type 1 diabetes: a multicenter analysis of 28 671 patients from the German / Austrian DPV-Wiss database. Diabetes Care 2010; 33: 2010-2012
13 Wenzlau JM, Juhl K, Yu L et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007; 104: 17040-17045
14 Verge CF, Howard NJ, Rowley MJ et al. Anti-glutamate decarboxylase and other antibodies at the onset of childhood IDDM: a population-based study. Diabetologia 1994; 37: 1113-1120
15 Seissler J, de Sonnaville JJ, Morgenthaler NG et al. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998; 41: 891-897
16 Cordell HJ, Todd JA. Multifactorial inheritance in type 1 diabetes. Trends Genet 1995; 11: 499-504
17 Huang W, Connor E, Rosa TD et al. Although DR3-DQB1*0201 may be associated with multiple component diseases of the autoimmune polyglandular syndromes, the human leukocyte antigen DR4-DQB1*0302 haplotype is implicated only in beta-cell autoimmunity. J Clin Endocrinol Metab 1996; 81: 2559-2263
18 Cantor AB, Krischer JP, Cuthbertson DD et al. Age and family relationship accentuate the risk of insulin-dependent diabetes mellitus (IDDM) in relatives of patients with IDDM. J Clin Endocrinol Metab 1995; 80: 3739-3743
19 American Diabetes Association (ADA). American Diabetes Association: clinical practice recommendations 1997. Diabetes Care 1997; 20 (Suppl. 01) 1-70
20 Imagawa A, Hanafusa T, Miyagawa J et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 2000; 342: 301-307
21 Deutsche Diabetes-Gesellschaft (DDG). Scherbaum WA, Kiess W. Definition, Klassifikation und Diagnostik des Diabetes mellitus. 2004 http://www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/EBL_Klassifikation_Update_2004.pdf
22 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553
23 El Achhab Y, Nejjari C, Chikri M et al. Disease-specific health-related quality of life instruments among adults diabetic: A systematic review. Diabetes Res Clin Pract 2008; 80: 171-184
24 DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986
25 Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341: 1306-1309
26 DCCT Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995; 102: 647-661
27 Canadian Diabetes Association. 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. 2008 http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf
28 American Diabetes Association (ADA). Standards of medical care in diabetes – 2010. Diabetes Care 2010; 33 (Suppl. 01) 11-61
29 Fanelli CG, Epifano L, Rambotti AM et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993; 42: 1683-1689
30 Fritsche A, Stefan N, Haring H et al. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes. Ann Intern Med 2001; 134: 729-736
31 Lachin JM, Genuth S, Nathan DM et al. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial – revisited. Diabetes 2008; 57: 995-1001
32 Lawson ML, Gerstein HC, Tsui E et al. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis. Diabetes Care 1999; 22 (Suppl. 02) B35-B39
33 Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653
34 Stettler C, Allemann S, Juni P et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J 2006; 152: 27-38
35 DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-1298
36 Nathan DM, Kuenen J, Borg R et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31: 1473-1478
37 Rohlfing CL, Wiedmeyer HM, Little RR et al. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275-278
38 Service FJ, O'Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 2001; 44: 1215-1220
39 Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006; 29: 1486-1490
40 Reinauer H, Scherbaum WA. Diabetes mellitus: Neuer Referenzstandard für HbA1c. Dtsch Arztebl 2009; 106: A-805-A-806
41 Gries FA, Bruns W, Grüneklee D. Therapieziele und Behandlungsstrategien beim Diabetes mellitus. Diabet Stoffw 2002; 11: 3-4
42 Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 2005; 54: 1-7
43 Kulzer B, Albus C, Herpertz S et al. Psychosoziales und Diabetes mellitus. Diabet Stoffw 2010; 5: S139-S145
44 Herpertz S, Petrak F, Albus C et al. Evidenzbasierte Diabetes-Leitlinie DDG: Psychosoziale Interventionen bei Patienten mit Diabetes mellitus. Diabet Stoffw 2003; 12: 35-58
45 Deutsche Diabetes-Gesellschaft (DDG): Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. Haak T, Kellerer M. Mainz: Kirchheim; 2009
46 Muis MJ, Bots ML, Bilo HJ et al. Determinants of daily insulin use in Type 1 diabetes. J Diabetes Complications 2006; 20: 356-360
47 Arai K, Yokoyama H, Okuguchi F et al. Association between body mass index and core components of metabolic syndrome in 1486 patients with type 1 diabetes mellitus in Japan (JDDM 13). Endocr J 2008; 55: 1025-1032
48 Waldhäusl W, Bratusch-Marrain P, Gasic S et al. Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man. Diabetologia 1979; 17: 221-227
49 Waldhäusl W. The physiological basis of insulin treatment – clinical aspects. Diabetologia 1986; 29: 837-849
50 Gray RS, Cowan P, Duncan LJ et al. Reversal of insulin resistance in type 1 diabetes following initiation of insulin treatment. Diabet Med 1986; 3: 18-23
51 Trout KK, Rickels MR, Schutta MH et al. Menstrual cycle effects on insulin sensitivity in women with type 1 diabetes: a pilot study. Diabetes Technol Ther 2007; 9: 176-182
52 Grigoryan OR, Grodnitskaya EE, Andreeva EN et al. Contraception in perimenopausal women with diabetes mellitus. Gynecol Endocrinol 2006; 22: 198-206
53 Scherbaum WA, Haak T. Deutsche Diabetes-Gesellschaft (DDG). Diabetes und Schwangerschaft. Evidenzbasierte Leitlinie der Deutschen Diabetes-Gesellschaft. 2008 http://www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/EBL_Schwangerschaft_2008.pdf
54 Elbelt U, Hahner S, Allolio B. Altered insulin requirement in patients with type 1 diabetes and primary adrenal insufficiency receiving standard glucocorticoid replacement therapy. Eur J Endocrinol 2009; 160: 919-924
55 Hasslacher C, Vogt C, Raupp D et al. Insulinbedarf bei Typ-1-Diabetikern mit nachlassender Nierenfunktion: Human-Insulin versus Analog-Insulin. Dtsch Med Wochenschr 2007; 132: 2500-2504
56 Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes 1996; 104: 106-110
57 White NH, Sun W, Cleary PA et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008; 126: 1707-1715
58 de Boer I, Kestenbaum B, Rue TC et al. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med 2008; 168: 1867-1873
59 Cleary PA, Orchard TJ, Genuth S et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006; 55: 3556-3565
60 Retnakaran R, Hochman J, DeVries JH et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004; 27: 2590-2596
61 Fatourechi MM, Kudva YC, Murad MH et al. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009; 94: 729-740
62 Jeitler K, Horvath K, Berghold A et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008; 51: 941-951
63 Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25: 765-774
64 Bolli GB, Kerr D, Thomas R et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009; 32: 1170-1176
65 Barnard KD, Lloyd CE, Skinner TC. Systematic literature review: quality of life associated with insulin pump use in Type 1 diabetes. Diabet Med 2007; 24: 607-617
66 Hoogma RP, Hammond PJ, Gomis R et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med 2006; 23: 141-147
67 Mukhopadhyay A, Farrell T, Fraser RB et al. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol 2007; 197: 447-456
68 Farrar D, Tuffnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev; 2007 CD005542
69 Chen R, Ben-Haroush A, Weismann-Brenner A et al. Level of glycemic control and pregnancy outcome in type 1 diabetes: a comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions. Am J Obstet Gynecol 2007; 197: 404-405
70 Cypryk K, Kosinski M, Kaminska P et al. Diabetes control and pregnancy outcomes in women with type 1 diabetes treated during pregnancy with continuous subcutaneous insulin infusion or multiple daily insulin injections. Pol Arch Med Wewn 2008; 118: 339-344
71 Gimenez M, Conget I, Nicolau J et al. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study. Acta Diabetol 2007; 44: 34-37
72 White R, Tata P, Burns T. Mood, learned resourcefulness and perceptions of control in type 1 diabetes mellitus. J Psychosom Res 1996; 40: 205-212
73 Bergenstal RM, Tamborlane WV, Ahmann A et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. N Engl J Med 2010; 1: 1-1
74 Diabetes Control and Complications Trial Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 361-376
75 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 1. Abschlussbericht. Auftrag A05-02. Version 1.0. 2007 http://www.iqwig.de/download/A05-02_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf
76 Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Diabetes Mellitus. Empfehlungen zur antihyperglykämischen Therapie des Diabetes mellitus Typ 2. 2009 2.. Auflage http://www.akdae.de/Arzneimitteltherapie/TE/Archiv/Diabetes.pdf
77 Heinemann L, Nosek L, Kapitza C et al. Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes. Diabetes Care 2009; 32: 1437-1439
78 Porcellati F, Rossetti P, Busciantella NR et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007; 30: 2447-2452
79 Heise T, Heinemann L, Hovelmann U et al. Biphasic insulin aspart 30 / 70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy. Diabetes Care 2009; 32: 1431-1433
80 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Langwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 1. Abschlussbericht. Auftrag A05-01. Version 1.0. 2010 http://www.iqwig.de/download/A05-01_Abschlussbericht_Langwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf
81 Singh SR, Ahmad F, Lal A et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009; 180: 385-397
82 Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009; 11: 372-378
83 Mullins P, Sharplin P, Yki-Jarvinen H et al. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29: 1607-1619
84 Ashwell SG, Bradley C, Stephens JW et al. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care 2008; 31: 1112-1117
85 Hermansen K, Fontaine P, Kukolja KK et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629
86 Drejer K. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 1992; 8: 259-285
87 Hansen BF, Danielsen GM, Drejer K et al. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 1996; 315 (Pt 1): 271-279
88 Ish-Shalom D, Christoffersen CT, Vorwerk P et al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997; 40 (Suppl. 02) S25-S31
89 Kurtzhals P, Schaffer L, Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005
90 Kellerer M, Haring HU. Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties. Exp Clin Endocrinol Diabetes 2001; 109: 63-64
91 Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-1744
92 Jonasson JM, Ljung R, Talback M et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745-1754
93 Ljung R, Talback M, Haglund B et al. Insulin glargine use and short-term incidence of malignancies – a three-year population-based observation. Acta Oncol 2011; 50: 685-693
94 Rosenstock J, Fonseca V, McGill JB et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009; 52: 1971-1973
95 Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52: 1755-1765
96 Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777
97 Smith U, Gale EA. Does diabetes therapy influence the risk of cancer?. Diabetologia 2009; 52: 1699-1708
98 Müssig K, Staiger H, Kantartzis K et al. Diabetes, Insulin, Insulinanaloga und Karzinome. Dtsch Med Wochenschr 2010; 135: 924-929
99 Grimaldi-Bensouda L, Marty M, Pollak M et al. The international study of insulin and cancer. Lancet 2010; 376: 769-770
100 Luijf YM, DeVries JH. Dosing accuracy of insulin pens versus conventional syringes and vials. Diabetes Technol Ther 2010; 12 (Suppl. 01) S73-S77
101 Frid A, Hirsch L, Gaspar R et al. New injection recommendations for patients with diabetes. Diabetes Metab 2010; 36 (Suppl. 02) 3-18
102 Brunner GA, Hirschberger S, Sendlhofer G et al. Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus. Diabet Med 2000; 17: 371-375
103 Rave K, Klein O, Frick AD et al. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 2006; 29: 1812-1817
104 Scheen AJ, Letiexhe MR, Lefebvre PJ. Minimal influence of the time interval between injection of regular insulin and food intake on blood glucose control of type diabetic patients on a basal-bolus insulin scheme. Diabetes Metab 1999; 25: 157-162
105 DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003; 289: 2254-2264
106 Lean ME, Ng LL, Tennison BR. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. Br Med J (Clin Res Ed) 1985; 290: 105-108
107 Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999; 43: 137-142
108 Vignati L, Anderson JH Jr, Iversen PW. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Clin Ther 1997; 19: 1408-1421
109 Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract 2007; 77: 231-236
110 Johansson UB, Amsberg S, Hannerz L et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care 2005; 28: 2025-2027
111 Bird P, Fowler I, Boyle MJ. Early rapid onset lipohypertrophy in a patient with type 1 diabetes mellitus. Aust N Z J Med 1998; 28: 467-468
112 Yosipovitch G, Hodak E, Vardi P et al. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes Care 1998; 21: 506-509
113 Pavlovic MD, Milenkovic T, Dinic M et al. The prevalence of cutaneous manifestations in young patients with type 1 diabetes. Diabetes Care 2007; 30: 1964-1967
114 Kordonouri O, Lauterborn R, Deiss D. Lipohypertrophy in young patients with type 1 diabetes. Diabetes Care 2002; 25: 634-634
115 Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. BMJ 2003; 327: 383-384
116 Lopez X, Castells M, Ricker A et al. Human insulin analog – induced lipoatrophy. Diabetes Care 2008; 31: 442-444
117 Hussein SF, Siddique H, Coates P et al. Lipoatrophy is a thing of the past, or is it?. Diabet Med 2007; 24: 1470-1472
118 Arranz A, Andia V, Lopez-Guzman A. A case of lipoatrophy with Lispro insulin without insulin pump therapy. Diabetes Care 2004; 27: 625-626
119 Murao S, Hirata K, Ishida T et al. Lipoatrophy induced by recombinant human insulin injection. Intern Med 1998; 37: 1031-1033
120 Richardson T, Weiss M, Thomas P et al. Day after the night before: influence of evening alcohol on risk of hypoglycemia in patients with type 1 diabetes. Diabetes Care 2005; 28: 1801-1802
121 Toeller M. Evidenz-basierte Ernährungsempfehlungen zur Behandlung und Prävention des Diabetes mellitus. Diabet Stoffw 2005; 14: 75-94
122 Turner BC, Jenkins E, Kerr D et al. The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. Diabetes Care 2001; 24: 1888-1893
123 Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med 2004; 140: 211-219
124 Hermanns N, Kulzer B, Krichbaum M. Problemspezifische Patientenschulung. Übersicht zu einem wesentlichen Bestandteil der Diabetestherapie. Diabetologe 2008; 4: 361-367
125 Hermanns N, Kulzer B. Diabetesschulung – ein kritischer Überblick. Diabetologe 2008; 4: 209-226
126 Mühlhauser I, Bruckner I, Berger M et al. Evaluation of an intensified insulin treatment and teaching programme as routine management of type 1 (insulin-dependent) diabetes. The Bucharest-Dusseldorf Study. Diabetologia 1987; 30: 681-690
127 Sämann A, Mühlhauser I, Bender R et al. Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. Diabetologia 2005; 48: 1965-1970
128 Bott S, Bott U, Berger M et al. Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia 1997; 40: 926-932
129 DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 2002; 325: 746-746
130 Cox D, Gonder-Frederick L, Polonsky W et al. A multicenter evaluation of blood glucose awareness training – II. Diabetes Care 1995; 18: 523-528
131 Cox DJ, Gonder-Frederick L, Julian DM et al. Long-term follow-up evaluation of blood glucose awareness training. Diabetes Care 1994; 17: 1-5
132 Cox DJ, Gonder-Frederick L, Polonsky W et al. Blood glucose awareness training (BGAT-2): long-term benefits. Diabetes Care 2001; 24: 637-642
133 Broers S, le CessieS, van Vliet KP et al. Blood Glucose Awareness Training in Dutch Type 1 diabetes patients. Short-term evaluation of individual and group training. Diabet Med 2002; 19: 157-161
134 Kinsley BT, Weinger K, Bajaj M et al. Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes. Diabetes Care 1999; 22: 1022-1028
135 Schachinger H, Hegar K, Hermanns N et al. Randomized controlled clinical trial of Blood Glucose Awareness Training (BGAT III) in Switzerland and Germany. J Behav Med 2005; 28: 587-594
136 Albano MG, Crozet C, d’Ivernois JF. Analysis of the 2004–2007 literature on therapeutic patient education in diabetes: results and trends. Acta Diabetol 2008; 45: 211-219
137 Cochran J, Conn VS. Meta-analysis of quality of life outcomes following diabetes self-management training. Diabetes Educ 2008; 34: 815-823
138 Warsi A, Wang PS, LaValley MP et al. Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med 2004; 164: 1641-1649
139 Chodosh J, Morton SC, Mojica W et al. Meta-analysis: chronic disease self-management programs for older adults. Ann Intern Med 2005; 143: 427-438
140 Norris SL, Nichols PJ, Caspersen CJ et al. Increasing diabetes self-management education in community settings. A systematic review. Am J Prev Med 2002; 22: 39-66
141 Ellis SE, Speroff T, Dittus RS et al. Diabetes patient education: a meta-analysis and meta-regression. Patient Educ Couns 2004; 52: 97-105
142 Lenz M, Steckelberg A, Richter B et al. Meta-analysis does not allow appraisal of complex interventions in diabetes and hypertension self-management: a methodological review. Diabetologia 2007; 50: 1375-1383
143 Bendik CF, Keller U, Moriconi N et al. Training in flexible intensive insulin therapy improves quality of life, decreases the risk of hypoglycaemia and ameliorates poor metabolic control in patients with type 1 diabetes. Diabetes Res Clin Pract 2009; 83: 327-333
144 Hermanns N, Kulzer B, Kubiak T et al. The effect of an education programme (HyPOS) to treat hypoglycaemia problems in patients with type 1 diabetes. Diabetes Metab Res Rev 2007; 23: 528-538
145 Hermanns N, Kulzer B, Kubiak T et al. Langfristige Effektivität eines neuen Schulungs- und Behandlungsprogramms für insulinpflichtige Diabetiker mit Hypoglykämieproblemen (HyPOS) auf die Inzidenz schwerer Hypoglykämien. Diabet Stoffw 2008; 3: A19-A19
146 Hermanns N, Kulzer B, Krichbaum M et al. Long-term effect of an education program (HyPOS) on the incidence of severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 2010; 33: e36-e36
147 Krakow D, Feulner-Krakow G, Giese M et al. Evaluation der LINDA Diabetes-Selbstmanagementschulung. Diabetes Stoffw 2004; 13: 77-89
148 Kulzer B, Krichbaum M, Hermanns N. Diabetesschulung – was ist zeitgemäß, was ist gesichert?. Diabetologe 2008; 4: 337-347
149 Hirsch A, Taiyeva O, Clever HU. Evaluation der Schulung „Den Füßen zuliebe“ für Risikopatienten nach 6 Monaten. Diabetes Stoffw 2004; 13: 67-76
150 Lincoln NB, Radford KA, Game FL et al. Education for secondary prevention of foot ulcers in people with diabetes: a randomised controlled trial. Diabetologia 2008; 51: 1954-1961
151 Müller UA, Hunger-Dathe W, Müller N et al. Langzeitglykämie und Hypoglykämien nach Teilnahme am strukturierten Behandlungs- und Schulungsprogramm „Insulinpumpen-Therapie für erwachsene Patienten mit Diabetes mellitus Typ 1“ von Roche Diagnostics GmbH. Diabet Stoffw 2007; 2: 161-168
152 Deutsche Diabetes-Gesellschaft (DDG). Scherbaum WA, Haak T. Körperliche Aktivität und Diabetes mellitus. Evidenzbasierte Leitlinie der Deutschen Diabetes-Gesellschaft. 2008 http://www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/EBL_Bewegung_2008.pdf
153 Goldberg PA, Siegel MD, Sherwin RS et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 2004; 27: 461-467
154 Studer C, Sankou W, Penfornis A et al. Efficacy and safety of an insulin infusion protocol during and after cardiac surgery. Diabetes Metab 2010; 36: 71-78
155 McConnell YJ, Johnson PM, Porter GA. Surgical site infections following colorectal surgery in patients with diabetes: association with postoperative hyperglycemia. J Gastrointest Surg 2009; 13: 508-515
156 Ramos M, Khalpey Z, Lipsitz S et al. Relationship of perioperative hyperglycemia and postoperative infections in patients who undergo general and vascular surgery. Ann Surg 2008; 248: 585-591
157 Gale SC, Sicoutris C, Reilly PM et al. Poor glycemic control is associated with increased mortality in critically ill trauma patients. Am Surg 2007; 73: 454-460
158 Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003; 78: 1471-1478
159 Capes SE, Hunt D, Malmberg K et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001; 32: 2426-2432
160 Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367
161 Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008; 300: 933-944
162 Brunkhorst FM, Engel C, Bloos F et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-139
163 Griesdale DE, de Souza RJ, van Dam RM et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 2009; 180: 821-827
164 Adams G, Hunter J, Langley J. Is nurse-managed blood glucose control in critical care as safe and effective as the traditional sliding scale method?. Intensive Crit Care Nurs 2009; 25: 294-305
165 Thorell A, Nygren J, Hirshman MF et al. Surgery-induced insulin resistance in human patients: relation to glucose transport and utilization. Am J Physiol 1999; 276: E754-E761
166 Golden SH, Peart-Vigilance C, Kao WH et al. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care 1999; 22: 1408-1414
167 Husband DJ, Thai AC, Alberti KG. Management of diabetes during surgery with glucose-insulin-potassium infusion. Diabet Med 1986; 3: 69-74
168 Latson TW, Ashmore TH, Reinhart DJ et al. Autonomic reflex dysfunction in patients presenting for elective surgery is associated with hypotension after anesthesia induction. Anesthesiology 1994; 80: 326-337
169 Burgos LG, Ebert TJ, Asiddao C et al. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology 1989; 70: 591-597
170 Ishihara H, Singh H, Giesecke AH. Relationship between diabetic autonomic neuropathy and gastric contents. Anesth Analg 1994; 78: 943-947
171 Christiansen CL, Schurizek BA, Malling B et al. Insulin treatment of the insulin-dependent diabetic patient undergoing minor surgery. Continuous intravenous infusion compared with subcutaneous administration. Anaesthesia 1988; 43: 533-537
172 Raucoules-Aime M, Roussel LJ, Rossi D et al. Effect of severity of surgery on metabolic control and insulin requirements in insulin-dependent diabetic patients. Br J Anaesth 1995; 74: 231-233
173 Furnary AP, Zerr KJ, Grunkemeier GL et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67: 352-360
174 World Health Organization (WHO). Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-253-i-253
175 Nathan DM, Zinman B, Cleary PA et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial / epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med 2009; 169: 1307-1316
176 Pang TT, Narendran P. Addressing insulin resistance in Type 1 diabetes. Diabet Med 2008; 25: 1015-1024
177 Jacobsen IB, Henriksen JE, Beck-Nielsen H. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin Pharmacol Toxicol 2009; 105: 145-149
178 Lund SS, Tarnow L, Astrup AS et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One 2008; 3: e3363-e3363
179 Dewey CM, Riley WJ. Have diabetes, will travel. Postgrad Med 1999; 105: 111-118 124
180 Pfohl M, Schmülling RM. Diabetes, Sport und Reisen. In: Schatz H. Diabetologie kompakt. Blackwell; 2001
181 Sane T, Koivisto VA, Nikkanen P et al. Adjustment of insulin doses of diabetic patients during long distance flights. BMJ 1990; 301: 421-422
182 Driessen SO, Cobelens FG, Ligthelm RJ. Travel-related morbidity in travelers with insulin-dependent diabetes mellitus. J Travel Med 1999; 6: 12-15
183 Schmülling RM, Pfohl M, Renn W et al. Flugreisen trotz Diabetes? Der Einfluß einer westlichen und östlichen Zeitverschiebung auf den Rhythmus zirkadianer Hormone und die Stoffwechseleinstellung von Typ I-Diabetikern. Z Allg Med 1995; 71: 212-225
184 Gandhi GY, Murad MH, Flynn DN et al. Immunotherapeutic agents in type 1 diabetes: a systematic review and meta-analysis of randomized trials. Clin Endocrinol (Oxf) 2008; 69: 244-252
185 Huurman VA, Decochez K, Mathieu C et al. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007; 23: 269-275
186 Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361: 2143-2152
187 Raz I, Avron A, Tamir M et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 2007; 23: 292-298
188 Schloot NC, Meierhoff G, Lengyel C et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007; 23: 276-285
189 Walter M, Philotheou A, Bonnici F et al. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 2009; 32: 2036-2040
190 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes – Nierenerkrankungen bei Diabetes im Erwachsenenalter. Version Konsultation 1.0. 2010 http://www.diabetes.versorgungsleitlinie.de
191 Panero F, Novelli G, Zucco C et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 2009; 32: 301-305
192 Steffes MW, Sibley S, Jackson M et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832-836
193 Ludvigsson J, Faresjo M, Hjorth M et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359: 1909-1920
194 Keymeulen B, Walter M, Mathieu C et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53: 614-623
195 Rother KI, Spain LM, Wesley RA et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care 2009; 32: 2251-2257
196 Sollinger HW, Odorico JS, Becker YT et al. One Thousand Simultaneous Pancreas-Kidney Transplants at a Single Center With 22-Year Follow-Up. Ann Surg 2009; 250: 618-630
197 Decker E, Coimbra C, Weekers L et al. A retrospective monocenter review of simultaneous pancreas-kidney transplantation. Transplant Proc 2009; 41: 3389-3392
198 Sutherland DE, Gruessner RW, Dunn DL et al. Lessons learned from more than 1000 pancreas transplants at a single institution. Ann Surg 2001; 233: 463-501
199 Landgraf R, Land W. Pankreastransplantation. In: Mehnert H, Standl E, Usadel H, Haring HU. Diabetologie in Klinik und Praxis. 5th. ed. Stuttgart: Thieme; 2003: 290-297
200 Robertson RP. Seminars in medicine of the Beth Israel Hospital, Boston: Pancreatic and islet transplantation for diabetes – cures or curiosities?. N Engl J Med 1992; 327: 1861-1868
201 Landgraf R. Impact of pancreas transplantation on diabetic secondary complications and quality of life. Diabetologia 1996; 39: 1415-1424
202 Robertson RP, Holohan TV, Genuth S. Therapeutic controversy: Pancreas transplantation for type diabetes. J Clin Endocrinol Metab 1998; 83: 1868-1874
203 National Institute for Health and Clinical Excellence (NICE). Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus: guidance. 2008 http://guidance.nice.org.uk/IPG257
204 Angelico MC, Alejandro R, Nery J et al. Transplantation of islets of Langerhans in patients with insulin-requiring diabetes mellitus undergoing orthotopic liver transplantation – the Miami experience. J Mol Med 1999; 77: 144-147
205 Brooks-Worrell BM, Peterson KP, Peterson CM et al. Reactivation of type 1 diabetes in patients receiving human fetal pancreatic tissue transplants without immunosuppression. Transplantation 2000; 69: 166-172
206 Shapiro AM, Ricordi C, Hering BJ et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318-1330
207 Ryan EA, Paty BW, Senior PA et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-2069
208 Universitätsklinikum Gießen. International Islet Transplant Registry. 2010 http://www.med.uni-giessen.de/itr/
209 Lakey JR, Mirbolooki M, Shapiro AM. Current status of clinical islet cell transplantation. Humana Pr; 2006
210 Nordrheinische Gemeinsame Einrichtung Disease-Management-Programme. Qualitätssicherungsbericht 2008. Disease-Management-Programme in Nordrhein. Brustkrebs, Diabetes mellitus Typ 1 / Typ 2, Koronare Herzkrankheit, Asthma / COPD. Düsseldorf: Nordrheinische Gemeinsame Einrichtung DMP; 2009
211 Kitabchi AE, Umpierrez GE, Miles JM et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32: 1335-1343
212 Kitabchi AE, Umpierrez GE, Murphy MB et al. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006; 29: 2739-2748
213 Bull SV, Douglas IS, Foster M et al. Mandatory protocol for treating adult patients with diabetic ketoacidosis decreases intensive care unit and hospital lengths of stay: results of a nonrandomized trial. Crit Care Med 2007; 35: 41-46
214 Foster DW, McGarry JD. The metabolic derangements and treatment of diabetic ketoacidosis. N Engl J Med 1983; 309: 159-169
215 Waldhäusl W, Kleinberger G, Korn A et al. Severe hyperglycemia: effects of rehydration on endocrine derangements and blood glucose concentration. Diabetes 1979; 28: 577-584
216 Kitabchi AE, Murphy MB, Spencer J et al. Is a priming dose of insulin necessary in a low-dose insulin protocol for the treatment of diabetic ketoacidosis?. Diabetes Care 2008; 31: 2081-2085
217 Kitabchi AE, Ayyagari V, Guerra SM. The efficacy of low-dose versus conventional therapy of insulin for treatment of diabetic ketoacidosis. Ann Intern Med 1976; 84: 633-638
218 Heber D, Molitch ME, Sperling MA. Low-dose continuous insulin therapy for diabetic ketoacidosis. Prospective comparison with “conventional” insulin therapy. Arch Intern Med 1977; 137: 1377-1380
219 Butkiewicz EK, Leibson CL, O’Brien PC et al. Insulin therapy for diabetic ketoacidosis. Bolus insulin injection versus continuous insulin infusion. Diabetes Care 1995; 18: 1187-1190
220 Fort P, Waters SM, Lifshitz F. Low-dose insulin infusion in the treatment of diabetic ketoacidosis: bolus versus no bolus. J Pediatr 1980; 96: 36-40
221 Lindsay R, Bolte RG. The use of an insulin bolus in low-dose insulin infusion for pediatric diabetic ketoacidosis. Pediatr Emerg Care 1989; 5: 77-79
222 Umpierrez GE, Latif K, Stoever J et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med 2004; 117: 291-296
223 Umpierrez GE, Jones S, Smiley D et al. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial. Diabetes Care 2009; 32: 1164-1169
224 Mazer M, Chen E. Is subcutaneous administration of rapid-acting insulin as effective as intravenous insulin for treating diabetic ketoacidosis?. Ann Emerg Med 2009; 53: 259-263
225 Ersoz HO, Ukinc K, Kose M et al. Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. Int J Clin Pract 2006; 60: 429-433
226 Della MannaT, Steinmetz L, Campos PR et al. Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. Diabetes Care 2005; 28: 1856-1861
227 Umpierrez GE, Cuervo R, Karabell A et al. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 2004; 27: 1873-1878
228 Hale PJ, Crase J, Nattrass M. Metabolic effects of bicarbonate in the treatment of diabetic ketoacidosis. Br Med J (Clin Res Ed) 1984; 289: 1035-1038
229 Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic ketoacidosis. Ann Intern Med 1986; 105: 836-840
230 Gamba G, Oseguera J, Castrejon M et al. Bicarbonate therapy in severe diabetic ketoacidosis. A double blind, randomized, placebo controlled trial. Rev Invest Clin 1991; 43: 234-238
231 Viallon A, Zeni F, Lafond P et al. Does bicarbonate therapy improve the management of severe diabetic ketoacidosis?. Crit Care Med 1999; 27: 2690-2693
232 Kitabchi AE, Umpierrez GE, Fisher JN et al. Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab 2008; 93: 1541-1552
233 Levin DL. Cerebral edema in diabetic ketoacidosis. Pediatr Crit Care Med 2008; 9: 320-329
234 Chiasson JL, ris-Jilwan N, Belanger R et al. Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. CMAJ 2003; 168: 859-866
235 Magee MF, Bhatt BA. Management of decompensated diabetes. Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome. Crit Care Clin 2001; 17: 75-106
236 Graveling AJ, Frier BM. Hypoglycaemia: an overview. Prim Care Diabetes 2009; 3: 131-139
237 McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabet Med 2001; 18: 690-705
238 Frier BM. Defining hypoglycaemia: what level has clinical relevance?. Diabetologia 2009; 52: 31-34
239 Swinnen SG, Mullins P, Miller M et al. Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia. Diabetologia 2009; 52: 38-41
240 Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57: 3169-3176
241 Deary IJ, Hepburn DA, MacLeod KM et al. Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis. Diabetologia 1993; 36: 771-777
242 DCCT Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271-286
243 Pedersen-Bjergaard U. Severe hypoglycaemia in type 1 diabetes: impact of the renin-angiotensin system and other risk factors. Dan Med Bull 2009; 56: 193-207
244 Pedersen-Bjergaard U, Pramming S, Heller SR et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 2004; 20: 479-486
245 Leese GP, Wang J, Broomhall J et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003; 26: 1176-1180
246 Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994; 17: 697-703
247 ter BraakEW, Appelman AM, van de Laak M et al. Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care 2000; 23: 1467-1471
248 Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev 2003; 19: 232-240
249 Graveling AJ, Warren RE, Frier BM. Hypoglycaemia and driving in people with insulin-treated diabetes: adherence to recommendations for avoidance. Diabet Med 2004; 21: 1014-1019
250 Pramming S, Thorsteinsson B, Bendtson I et al. Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med 1991; 8: 217-222
251 Donnelly LA, Morris AD, Frier BM et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005; 22: 749-755
252 Gerich JE, Mokan M, Veneman T et al. Hypoglycemia unawareness. Endocr Rev 1991; 12: 356-371
253 Cranston I, Lomas J, Maran A et al. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994; 344: 283-287
254 Geddes J, Schopman JE, Zammitt NN et al. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med 2008; 25: 501-504
255 Clarke WL, Cox DJ, Gonder-Frederick LA et al. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 1995; 18: 517-522
256 Hoi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B. Classification of hypoglycemia awareness in people with type 1 diabetes in clinical practice. J Diabetes Complications 2010; 24: 392-397
257 Vignesh JP, Mohan V. Hypoglycaemia unawareness. J Assoc Physicians India 2004; 52: 727-732
258 Geddes J, Wright RJ, Zammitt NN et al. An evaluation of methods of assessing impaired awareness of hypoglycemia in type 1 diabetes. Diabetes Care 2007; 30: 1868-1870
259 Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev 2008; 29: 494-511
260 Jacobson AM, Musen G, Ryan CM et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356: 1842-1852
261 Brismar T, Maurex L, Cooray G et al. Predictors of cognitive impairment in type 1 diabetes. Psychoneuroendocrinology 2007; 32: 1041-1051
262 Brands AM, Biessels GJ, de Haan EH et al. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care 2005; 28: 726-735
263 Stork AD, van Haeften TW, Veneman TF. Diabetes and driving: Desired data, research methods and their pitfalls, current knowledge, and future research. Diabetes Care 2006; 29: 1942-1949
264 Harsch IA, Stocker S, Radespiel-Troger M et al. Traffic hypoglycaemias and accidents in patients with diabetes mellitus treated with different antidiabetic regimens. J Intern Med 2002; 252: 352-360
265 Laing SP, Swerdlow AJ, Slater SD et al. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999; 16: 466-471
266 DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991; 90: 450-459
267 Beck RW, Buckingham B, Miller K et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care 2009; 32: 1947-1953
268 O'Connell MA, Donath S, O’Neal DN et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia 2009; 52: 1250-1257
269 Bode B, Beck RW, Xing D et al. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care 2009; 32: 2047-2049
270 Tamborlane WV, Beck RW, Bode BW et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359: 1464-1476
271 Coster S, Gulliford MC, Seed PT et al. Monitoring blood glucose control in diabetes mellitus: a systematic review. Health Technol Assess 2000; 4: i-93-i-93
272 Gordon D, Semple CG, Paterson KR. Do different frequencies of self-monitoring of blood glucose influence control in type 1 diabetic patients?. Diabet Med 1991; 8: 679-682
273 Terent A, Hagfall O, Cederholm U. The effect of education and self-monitoring of blood glucose on glycosylated hemoglobin in type I diabetes. A controlled 18-month trial in a representative population. Acta Med Scand 1985; 217: 47-53
274 Worth R, Home PD, Johnston DG et al. Intensive attention improves glycaemic control in insulin-dependent diabetes without further advantage from home blood glucose monitoring: results of a controlled trial. Br Med J (Clin Res Ed) 1982; 285: 1233-1240
275 Schütt M, Kern W, Krause U et al. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24 500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes 2006; 114: 384-388
276 Alto WA, Meyer D, Schneid J et al. Assuring the accuracy of home glucose monitoring. J Am Board Fam Pract 2002; 15: 1-6
277 Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 2006; 295: 1688-1697
278 Bergenstal R, Pearson J, Cembrowski GS et al. Identifying variables associated with inaccurate self-monitoring of blood glucose: proposed guidelines to improve accuracy. Diabetes Educ 2000; 26: 981-989
279 Chetty VT, Almulla A, Odueyungbo A et al. The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HBA1c) levels in Type I diabetic patients: a systematic review. Diabetes Res Clin Pract 2008; 81: 79-87
280 Cooke D, Hurel SJ, Casbard A et al. Randomized controlled trial to assess the impact of continuous glucose monitoring on HbA(1c) in insulin-treated diabetes (MITRE Study). Diabet Med 2009; 26: 540-547
281 Raccah D, Sulmont V, Reznik Y et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care 2009; 32: 2245-2250
282 Hirsch IB, Abelseth J, Bode BW et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther 2008; 10: 377-383
283 Kubiak T, Hermanns N, Schreckling HJ et al. Assessment of hypoglycaemia awareness using continuous glucose monitoring. Diabet Med 2004; 21: 487-490
284 Streja D. Can continuous glucose monitoring provide objective documentation of hypoglycemia unawareness?. Endocr Pract 2005; 11: 83-90
285 Choudhary P, Geddes J, Freeman JV et al. Frequency of biochemical hypoglycaemia in adults with Type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring. Diabet Med 2010; 27: 666-672
286 Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV). Nationale VersorgungsLeitlinie Typ-2-Diabetes-Prävention und Therapie von Netzhautkomplikationen. 2006 http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_netzhaut/index_html
287 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Neuropathie bei Diabetes im Erwachsenenalter. 2010 http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_neuro
288 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes – Präventions- und Behandlungsstrategien für Fußkomplikationen. Version 2.8. 2006 http://www.diabetes.versorgungsleitlinie.de
289 Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV). Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter. Langfassung. 2010 http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_nephro
290 Warram JH, Gearin G, Laffel L et al. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin / creatinine ratio. J Am Soc Nephrol 1996; 7: 930-937
291 Krolewski AS, Laffel LM, Krolewski M et al. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 332: 1251-1255
292 Krolewski M, Eggers PW, Warram JH. Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int 1996; 50: 2041-2046
293 Orchard TJ, Secrest AM, Miller RG et al. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010; 53: 2312-2319
294 Groop PH, Thomas MC, Moran JL et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009; 58: 1651-1658
295 Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653
296 Klein R, Klein BE, Moss SE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989; 107: 237-243
297 White NH, Sun W, Cleary PA et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT / EDIC: comparison of adults and adolescents. Diabetes 2010; 59: 1244-1253
298 Hammes HP, Lemmen KD, Bertram B. Diabetische Retinopathie und Makulopathie. Diabet Stoffw 2009; 4: S131-S135
299 Moss SE, Klein R, Kessler SD et al. Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy. Ophthalmology 1985; 92: 62-67
300 Klein R, Klein BE, Neider MW et al. Diabetic retinopathy as detected using ophthalmoscopy, a nonmydriatic camera and a standard fundus camera. Ophthalmology 1985; 92: 485-491
301 Aiello LP, Gardner TW, King GL et al. Diabetic retinopathy. Diabetes Care 1998; 21: 143-156
302 Kroll P, Bertram B. Augenfachärztlicher Untersuchungsbogen zur Früherkennung diabetischer Augenerkrankungen. Z prakt Augenheilkd 1997; 18: 351-362
303 Pirart J, Lauvaux JP, Rey W. Blood sugar and diabetic complications. N Engl J Med 1978; 298: 1149-1149
304 Young MJ, Boulton AJ, MacLeod AF et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-154
305 Tesfaye S, Stevens LK, Stephenson JM et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996; 39: 1377-1384
306 Dyck PJ, Kratz KM, Karnes JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-824
307 Ziegler D, Gries FA, Muhlen H et al. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. The Diacan Multicenter Study Group. Diabete Metab 1993; 19: 143-151
308 Lluch I, Hernandez A, Real JT et al. Cardiovascular autonomic neuropathy in type 1 diabetic patients with and without peripheral neuropathy. Diabetes Res Clin Pract 1998; 42: 35-40
309 Colhoun HM, Francis DP, Rubens MB et al. The association of heart-rate variability with cardiovascular risk factors and coronary artery calcification: a study in type 1 diabetic patients and the general population. Diabetes Care 2001; 24: 1108-1114
310 Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med 2007; 356: 820-829
311 Samann A, Tajiyeva O, Muller N et al. Prevalence of the diabetic foot syndrome at the primary care level in Germany: a cross-sectional study. Diabet Med 2008; 25: 557-563
312 Leese GP, Reid F, Green V et al. Stratification of foot ulcer risk in patients with diabetes: a population-based study. Int J Clin Pract 2006; 60: 541-545
313 Heller G, Günster C, Swart E. Über die Häufigkeit von Amputationen unterer Extremitäten in Deutschland. Dtsch Med Wochenschr 2005; 130: 1689-1690
314 Allemann S, Saner C, Zwahlen M et al. Long-term cardiovascular and non-cardiovascular mortality in women and men with type 1 and type 2 diabetes mellitus: a 30-year follow-up in Switzerland. Swiss Med Wkly 2009; 139: 576-583
315 American Diabetes Association (ADA). Standards of medical care in diabetes – 2010. Diabetes Care 2010; 33: S11-S61
316 Deutsche Diabetes-Gesellschaft (DDG). Scherbaum WA, Kerner W. Diagnostik und Therapie von Herzerkrankungen bei Diabetes mellitus. Evidenzbasierte Leitlinie der DDG. 2006 http://www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/EBL_Herz_Update_2006.pdf